Renal glucose reabsorption inhibitors to treat diabetes.
about
Patient considerations in type 2 diabetes - role of combination dapagliflozin-metformin XRTight junction proteins and oxidative stress in heavy metals-induced nephrotoxicitySodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsPharmacogenomics in diabetes mellitus: insights into drug action and drug discoveryMesenchymal Stem Cells as Therapeutic Candidates for Halting the Progression of Diabetic Nephropathy55P0110, a Novel Synthetic Compound Developed from a Plant Derived Backbone Structure, Shows Promising Anti-Hyperglycaemic Activity in MiceInfluence of Familial Renal Glycosuria Due to Mutations in the SLC5A2 Gene on Changes in Glucose Tolerance over TimePharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.The Concise Guide to PHARMACOLOGY 2013/14: transporters.SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data.Fasting plasma glucose and serum uric acid levels in a general Chinese population with normal glucose tolerance: A U-shaped curve.Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet.Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitusCurrent therapies and emerging drugs in the pipeline for type 2 diabetes.Emerging treatments in type 2 diabetes: focus on canagliflozin.Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus.SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuriaExposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology.Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice.LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.Extract of Sesbania grandiflora Ameliorates Hyperglycemia in High Fat Diet-Streptozotocin Induced Experimental Diabetes Mellitus.Population Pharmacokinetics and Exposure-Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes.Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trialLong-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.Insulin therapy in people with type 2 diabetes: opportunities and challenges?Effects of SGLT2 inhibitors on cardiovascular outcomes.Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents.Individualized glycaemic targets and pharmacotherapy in type 2 diabetes.Canagliflozin: first global approval.Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.Empagliflozin: a review of its use in patients with type 2 diabetes mellitus.Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans.Successful integration of nonclinical and clinical findings in interpreting the clinical relevance of rodent neoplasia with a new chemical entity.Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.
P2860
Q26766404-B12110E6-95DA-46CE-B484-ED1C5A2A7634Q27012765-90078CA0-0AC6-4616-BF13-6C2F8E9D0830Q28072765-02B0D82B-B16D-4896-94D1-5F2E51A9787CQ28274686-E6D32A22-FD95-4FA1-BAA8-BA5F79A62B76Q28354224-2EF9292C-5BF9-4344-BF24-04613EF2437FQ28547237-387CD1CC-3770-4012-A750-A9A89C3564A9Q28552106-7E5669F5-731D-42FD-9F0C-CA77D6DC0847Q30249371-94C9694E-08B3-4FDA-B753-C50E69080F04Q30486743-3178FC72-81FB-4BFC-8867-9E65B6EA0366Q33696974-7670C9C4-1985-4906-A594-AE6B7EFCBCC8Q33759610-4225110D-0300-498F-AA73-2144D138AE16Q33848499-31F81E55-7C9C-4456-A8D4-DA50BB5B7FD3Q33857698-F700FBEF-99B1-4A0B-93AD-4C3D71B77A3DQ33871321-D375379E-0BF6-450B-BD35-63E01F978DD8Q33928941-6349F95D-C90B-465D-ADFC-B1A059D42204Q34109789-05398CE3-E983-4536-9132-F90F30360B07Q34397646-95050FAD-366E-4B7D-93CC-53E518DDCE51Q34470786-600DE5E3-305E-46FA-8435-601832C43C95Q34635575-9737F47A-C25A-4A8D-B50B-AA0CC182469AQ34726437-F0F33214-5210-4898-B50D-112DA7B76144Q35952522-3EAB1392-8C36-445A-9ECF-EB9EE4FD6BAAQ36105649-47DB7762-C078-4AA6-9B6C-56690E425182Q36969821-F035A9DF-DAA5-4BDB-9225-261E1BBCBA06Q37239278-581E9911-FF18-4611-A9DF-7D0BA9F558CAQ37278239-E3A61AFD-4E4B-4721-9CC2-916BE4DF82D0Q37331262-03023EB2-AF4B-40FE-BD19-A17CF02FE904Q37461707-8B9E8ABE-0D51-4E7C-A2B3-31E11A626BEDQ37989674-76DC93D9-BBC4-4868-88A8-2D5E2C55622FQ38009886-9276730A-5FFF-4D1D-8DB3-D9963C1B66DAQ38109751-4693046E-7835-4538-A13B-7EA741DD671CQ38111292-BD822C68-E343-4701-90CB-BA4EF7235A53Q38175467-6B912BB0-ED53-4602-BABA-77B8A562C02EQ38255999-921C95C0-8A05-4ABA-9DA4-7208E571DE85Q38270203-EA774B14-2F59-43BD-B85F-E0AF73DD9DBAQ38340949-52EEFA2A-489F-4BD2-848E-208756936013Q38389823-1DBF666A-C914-44DD-9BE1-397D6312C191Q38537119-33A848D7-3275-4E8C-9F75-8074CB7B0A3CQ38562860-E19AB5F2-0E58-469D-A7EC-092A6C503078Q38573559-C4295A88-34A6-438E-8C35-20E8C933DD19Q38619164-EFBA04C0-FC30-4852-AE65-25BE6A337FCE
P2860
Renal glucose reabsorption inhibitors to treat diabetes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Renal glucose reabsorption inhibitors to treat diabetes.
@en
Renal glucose reabsorption inhibitors to treat diabetes.
@nl
type
label
Renal glucose reabsorption inhibitors to treat diabetes.
@en
Renal glucose reabsorption inhibitors to treat diabetes.
@nl
prefLabel
Renal glucose reabsorption inhibitors to treat diabetes.
@en
Renal glucose reabsorption inhibitors to treat diabetes.
@nl
P1476
Renal glucose reabsorption inhibitors to treat diabetes.
@en
P356
10.1016/J.TIPS.2010.11.011
P577
2011-01-04T00:00:00Z